Nature Reviews Gastroenterology & Hepatology

Article	Citations
Cholangiocarcinoma 2020: the next horizon in mechanisms and management	1110
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention	843
Molecular and cellular mechanisms of liver fibrosis and its regression	750
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	703
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics	638
Advances in immunotherapy for hepatocellular carcinoma	596
The four epidemiological stages in the global evolution of inflammatory bowel disease	493
Pancreatic cancer stroma: an update on therapeutic targeting strategies	445
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma	425
Liver regeneration: biological and pathological mechanisms and implications	421
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors	373
Dietary fibre in gastrointestinal health and disease	364
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments	343
Advancing the global public health agenda for NAFLD: a consensus statement	323
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods	319
COVID-19 and liver disease: mechanistic and clinical perspectives	260
Global burden of irritable bowel syndrome: trends, predictions and risk factors	244
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	243
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2	214
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications	198
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	184
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	180
Cell death in the gut epithelium and implications for chronic inflammation	179
Gut microbiome, big data and machine learning to promote precision medicine for cancer	172
The gut microbiome as a modulator of healthy ageing	169

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors	169
Therapeutic pipeline in nonalcoholic steatohepatitis	168
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer	166
COVID-19 and the other pandemic: populations made vulnerable by systemic inequity	159
AHR in the intestinal microenvironment: safeguarding barrier function	154
Cell death in pancreatic cancer: from pathogenesis to therapy	152
Role of liver sinusoidal endothelial cells in liver diseases	151
From NAFLD to MAFLD: when pathophysiology succeeds	150
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis	149
Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD	140
Cirrhosis-associated immune dysfunction	140
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer	138
The intestinal barrier, an arbitrator turned provocateur in IBD	134
Gastrointestinal biofilms in health and disease	127
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease	124
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology	123
Brain–gut–microbiome interactions in obesity and food addiction	120
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance	119
Evolving therapeutic landscape of advanced hepatocellular carcinoma	118
The role of goblet cells and mucus in intestinal homeostasis	118
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment	116
Progress towards elimination goals for viral hepatitis	114
Modern therapeutic approaches for the treatment of malignant liver tumours	114
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	112
Polyploidy in liver development, homeostasis and disease	109
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	108
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma	107
Current and future colorectal cancer screening strategies	105
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors	101
The evolution and clinical impact of hepatitis B virus genome diversity	101
COVID-19 and acute pancreatitis: examining the causality	99
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure	98
Disorders of the enteric nervous system — a holistic view	98
The pancreatic cancer genome revisited	96
NAFLD — sounding the alarm on a silent epidemic	91
Global epidemiology of cirrhosis — aetiology, trends and predictions	90
Nonalcoholic fatty liver disease: another leap forward	88
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	87
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology	87
Leveraging diet to engineer the gut microbiome	86
The role of oral bacteria in inflammatory bowel disease	82
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	80
Harnessing metabolic dependencies in pancreatic cancers	79
The metabolic nature of inflammatory bowel diseases	78
Recipient factors in faecal microbiota transplantation: one stool does not fit all	73
A risk-stratified approach to colorectal cancer prevention and diagnosis	72
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	71
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight	71
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology	69
Understanding the physiology of human defaecation and disorders of continence and evacuation	68

Defining comprehensive models of care for NAFLD	68
Early detection of pancreatic cancer using DNA-based molecular approaches	68
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism	68
Hippo signalling in the liver: role in development, regeneration and disease	66
Foundations of gastrointestinal-based drug delivery and future developments	66
Circadian clocks in the digestive system	65
Location is important: differentiation between ileal and colonic Crohn’s disease	65
Viral hepatitis and pregnancy	64
Intra-pancreatic fat deposition: bringing hidden fat to the fore	64
Breakthroughs in hepatitis C research: from discovery to cure	64
Current developments in gastric cancer: from molecular profiling to treatment strategy	64
Understanding, predicting and achieving liver transplant tolerance: from bench to bedside	63
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications	63
Maladaptive regeneration — the reawakening of developmental pathways in NASH and fibrosis	63
Postbiotics — when simplification fails to clarify	62
Current and emerging therapies for coeliac disease	61
Paracellular permeability and tight junction regulation in gut health and disease	61
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis	61
The promise of the gut microbiome as part of individualized treatment strategies	59
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment	57
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	55
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?	54
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease	54
Multiomics to elucidate inflammatory bowel disease risk factors and pathways	53
Human biomimetic liver microphysiology systems in drug development and precision medicine	53
Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease	52
Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation	51
Gastrointestinal post-acute COVID-19 syndrome	51
Global burden of hepatitis B virus: current status, missed opportunities and a call for action	51
Development of AI-based pathology biomarkers in gastrointestinal and liver cancer	50
COVID-19 and liver transplantation	50
Gut feelings: mechanosensing in the gastrointestinal tract	49
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	48
The immune microenvironment in gastric adenocarcinoma	48
Regulation and functional roles of chemokines in liver diseases	46
The war against pancreatic cancer in 2020 — advances on all fronts	44
Bacteriophages and their potential for treatment of gastrointestinal diseases	44
Hepatic inflammatory responses in liver fibrosis	43
COVID-19 and the liver-related deaths to come	43
Dietary management of adults with IBD — the emerging role of dietary therapy	41
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	41
Next-generation robotics in gastrointestinal surgery	41
Single-cell RNA sequencing in pancreatic cancer	41
When the minority tax is doubled: being Black and female in academic medicine	39
Updated epidemiology of gastrointestinal cancers in East Asia	39
The global burden of coeliac disease: opportunities and challenges	38
Optimizing immunotherapy for colorectal cancer	36
SARS-CoV-2 vaccination in IBD: more pros than cons	35
Head-to-head trials in inflammatory bowel disease: past, present and future	35
IgG4-related diseases of the digestive tract	35
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease	35
Therapeutic landscape and future direction of metastatic colorectal cancer	34
Extending treatment eligibility for chronic hepatitis B virus infection	34
Machine perfusion of the liver: applications in transplantation and beyond	29
COVID-19 and endoscopy: implications for healthcare and digestive cancer screening	29
The scientific basis of combination therapy for chronic hepatitis B functional cure	28
How academia should respond to racism	28
Hepatitis C virus elimination: laying the foundation for achieving 2030 targets	28
Gut–liver axis: barriers and functional circuits	28
Immunology and immunotherapy of cholangiocarcinoma	28
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	27
Transcriptional programmes underlying cellular identity and microbial responsiveness in the intestinal epithelium	27
Exploring liver cancer biology through functional genetic screens	27
Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract	26
Macrophages in intestinal homeostasis and inflammatory bowel disease	26
Nomenclature of HBV core protein-targeting antivirals	25
Lifestyle interventions in nonalcoholic fatty liver disease	25
What are the clinical settings and outcomes of lean NAFLD?	24
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	23
Methanogenic archaea in the human gastrointestinal tract	23
A framework for fibrolamellar carcinoma research and clinical trials	23
Artificial intelligence and automation in endoscopy and surgery	22
Capturing the environment of the Clostridioides difficile infection cycle	22
The microbiota and the gut–liver axis in primary sclerosing cholangitis	22
Reply to: Postbiotics — when simplification fails to clarify	20
The oral–gut axis in IBD	19
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	19
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	19
Modelling intestinal inflammation and infection using ‘mini-gut’ organoids	18
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	18

Mechanisms of pruritus in cholestasis: understanding and treating the itch	18
Improving IBD outcomes in the era of many treatment options	18
Precision medicine in IBD: genes, drugs, bugs and omics	18